Kamlesh Khunti to Glycated Hemoglobin A
This is a "connection" page, showing publications Kamlesh Khunti has written about Glycated Hemoglobin A.
Connection Strength
2.800
-
Risk of hypoglycaemia in people aged =65 years receiving linagliptin: pooled data from 1489 individuals with type 2 diabetes mellitus. Int J Clin Pract. 2018 Oct; 72(10):e13240.
Score: 0.413
-
Novel diabetes subgroups. Lancet Diabetes Endocrinol. 2018 06; 6(6):439.
Score: 0.403
-
Self-knowledge of HbA1c in people with Type 2 Diabetes Mellitus and its association with glycaemic control. Prim Care Diabetes. 2017 10; 11(5):414-420.
Score: 0.379
-
Associations of moderate-to-vigorous-intensity physical activity and body mass index with glycated haemoglobin within the general population: a cross-sectional analysis of the 2008 Health Survey for England. BMJ Open. 2017 04 03; 7(4):e014456.
Score: 0.372
-
Glycaemic control after treatment intensification in patients with type 2 diabetes uncontrolled on two or more non-insulin antidiabetic drugs in a real-world setting. Diabetes Obes Metab. 2019 06; 21(6):1373-1380.
Score: 0.107
-
GP-OSMOTIC trial protocol: an individually randomised controlled trial to determine the effect of retrospective continuous glucose monitoring (r-CGM) on HbA1c in adults with type 2 diabetes in general practice. BMJ Open. 2018 07 17; 8(7):e021435.
Score: 0.102
-
Changes in HbA1c and weight, and treatment persistence, over the 18 months following initiation of second-line therapy in patients with type 2 diabetes: results from the United Kingdom Clinical Practice Research Datalink. BMC Med. 2018 07 16; 16(1):116.
Score: 0.102
-
Association Between Type 2 Diabetes and All-Cause Hospitalization and Mortality in the UK General Heart Failure Population: Stratification by Diabetic Glycemic Control and Medication Intensification. JACC Heart Fail. 2018 01; 6(1):18-26.
Score: 0.096
-
Therapeutic inertia amongst general practitioners with interest in diabetes. Prim Care Diabetes. 2018 02; 12(1):87-91.
Score: 0.096
-
Older people with Type 2 diabetes, including those with chronic kidney disease or dementia, are commonly overtreated with sulfonylurea or insulin therapies. Diabet Med. 2017 09; 34(9):1219-1227.
Score: 0.094
-
Change in Sedentary Time, Physical Activity, Bodyweight, and HbA1c in High-Risk Adults. Med Sci Sports Exerc. 2017 06; 49(6):1120-1125.
Score: 0.094
-
Glycaemic control and hypoglycaemia burden in patients with type 2 diabetes initiating basal insulin in Europe and the USA. Diabetes Obes Metab. 2017 08; 19(8):1155-1164.
Score: 0.093
-
A randomized controlled trial comparing the GLP-1 receptor agonist liraglutide to a sulphonylurea as add on to metformin in patients with established type 2 diabetes during Ramadan: the Treat 4 Ramadan Trial. Diabetes Obes Metab. 2014 Jun; 16(6):527-36.
Score: 0.075
-
Self-titration of insulin in the management of people with type 2 diabetes: a practical solution to improve management in primary care. Diabetes Obes Metab. 2013 Aug; 15(8):690-700.
Score: 0.070
-
Cohort profile: National Diabetes Audit for England and Wales. Diabet Med. 2021 09; 38(9):e14616.
Score: 0.031
-
Treatment patterns and associated factors in 14 668 people with type 2 diabetes initiating a second-line therapy: Results from the global DISCOVER study programme. Diabetes Obes Metab. 2019 11; 21(11):2474-2485.
Score: 0.027
-
Update on the General Practice Optimising Structured Monitoring to Improve Clinical Outcomes in Type 2 Diabetes (GP-OSMOTIC) trial: statistical analysis plan for a multi-centre randomised controlled trial. Trials. 2019 Jan 30; 20(1):93.
Score: 0.026
-
Vascular complications in patients with type 2 diabetes: prevalence and associated factors in 38 countries (the DISCOVER study program). Cardiovasc Diabetol. 2018 11 28; 17(1):150.
Score: 0.026
-
Time to Treatment Intensification After Monotherapy Failure and Its Association With Subsequent Glycemic Control Among 93,515 Patients With Type 2 Diabetes. Diabetes Care. 2018 10; 41(10):2096-2104.
Score: 0.026
-
Alogliptin in Patients with Type 2 Diabetes Receiving Metformin and Sulfonylurea Therapies in the EXAMINE Trial. Am J Med. 2018 07; 131(7):813-819.e5.
Score: 0.025
-
Real-world use and modeled impact of glucose-lowering therapies evaluated in recent cardiovascular outcomes trials: An NCDR® Research to Practice project. Eur J Prev Cardiol. 2017 10; 24(15):1637-1645.
Score: 0.024
-
External national validation of the Leicester Self-Assessment score for Type 2 diabetes using data from the English Longitudinal Study of Ageing. Diabet Med. 2017 11; 34(11):1575-1583.
Score: 0.024
-
Therapeutic inertia in patients treated with two or more antidiabetics in primary care: Factors predicting intensification of treatment. Diabetes Obes Metab. 2018 01; 20(1):103-112.
Score: 0.024
-
Comorbidities, complications and mortality in people of South Asian ethnicity with type 1 diabetes compared with other ethnic groups: a systematic review. BMJ Open. 2017 Jul 13; 7(7):e015005.
Score: 0.024
-
What determines treatment satisfaction of patients with type 2 diabetes on insulin therapy? An observational study in eight European countries. BMJ Open. 2017 Jul 11; 7(7):e016180.
Score: 0.024
-
Towards an improved global understanding of treatment and outcomes in people with type 2 diabetes: Rationale and methods of the DISCOVER observational study program. J Diabetes Complications. 2017 Jul; 31(7):1188-1196.
Score: 0.023